"cyclin dependent kinase inhibitor 3" trang 2 - tải miễn phí từ tailieunhanh
Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression

Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
7    55    0
CDKN3 expression is an independent prognostic factor and associated with advanced tumor stage in nasopharyngeal carcinoma

CDKN3 expression is an independent prognostic factor and associated with advanced tumor stage in nasopharyngeal carcinoma
7    70    0
An association map on the effect of flavonoids on the signaling pathways in colorectal cancer

An association map on the effect of flavonoids on the signaling pathways in colorectal cancer
12    48    0
P16 as a marker of carcinoma in effusions and peritoneal washing

P16 as a marker of carcinoma in effusions and peritoneal washing
8    95    0
CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma

CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma
12    47    1
YWHA (14-3-3) protein isoforms and their interactions with CDC25B phosphatase in mouse oogenesis and oocyte maturation

YWHA (14-3-3) protein isoforms and their interactions with CDC25B phosphatase in mouse oogenesis and oocyte maturation
22    33    1
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
9    21    1
P21−/− mice exhibit enhanced bone regeneration after injury

P21−/− mice exhibit enhanced bone regeneration after injury
10    45    1
Inhibited growth of mesenchymal stem cells under simulated microgravity

Inhibited growth of mesenchymal stem cells under simulated microgravity
8    67    1
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER2−metastatic or advanced breast cancer patients: A network meta-analysis

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER2−metastatic or advanced breast cancer patients: A network meta-analysis
12    1    1
Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme

Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme
17    1    1
Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
12    1    1
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
10    5    1
An insight into the therapeutic potential of piperazine-based anticancer agents

An insight into the therapeutic potential of piperazine-based anticancer agents
23    76    1